(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

DERMOPLASMINE

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

DERMOPLASMINE

ST13

US500000079245543

Class

3, 5

Filing

79245543

Registration

5859479

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

36

Latest update

04/28/2026

Trademark type

Combined

Nice classes

3, 5

Filing date

10/08/2018

Registration date

09/17/2019

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/03/2026

Last transaction

04/28/2026

Responsible office

United States Patent and Trademark Office

Status code

709

Official register

Principal Register

Drawing code

5

Owner type

99

Owner location

FR

Examiner

AYALA, LOURDES

Law office

L60

Current location

GENERIC WEB UPDATE

Holders and representatives

Holders

BOIRON

Representatives

JANET G RICCIUTI JANET GILBERT RICCIUTI PC

Technical classification

Nice Classes

Class 3Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 3

Cosmetic productsnon-medicated cosmetic cream for treatment of skin irritations

Class 5

Pharmaceutical preparationshomeopathic and phytotherapeutic specialties for the treatment of irritation to the skin and nasal mucosa

Publications

History of USPTO decisions and trademark events.

36 publications found

C71T

CANCELLED SECTION 71

04/03/2026

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

09/17/2024

NREP

NEW REPRESENTATIVE AT IB RECEIVED

10/14/2023

INNA

INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE

12/05/2020

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

11/30/2020

CORR

CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED

04/01/2020

REIN

REINSTATED

03/31/2020

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

03/31/2020

CRCV

CORRECTION TRANSACTION RECEIVED FROM IB

03/20/2020

FINA

FINAL DISPOSITION REVIEWED - NO ACTION REQUIRED BY OFFICE

01/09/2020

DENC

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED

01/03/2020

DETH

DEATH OF INTERNATIONAL REGISTRATION

01/03/2020

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

12/17/2019

R.PR

REGISTERED-PRINCIPAL REGISTER

09/17/2019

RNWL

INTERNATIONAL REGISTRATION RENEWED

07/04/2019

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/02/2019

PUBO

PUBLISHED FOR OPPOSITION

07/02/2019

GPNX

NOTIFICATION PROCESSED BY IB

06/28/2019

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

06/12/2019

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

06/12/2019

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/12/2019

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/28/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/25/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/25/2019

ALIE

ASSIGNED TO LIE

05/25/2019

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/21/2019

RFNT

REFUSAL PROCESSED BY IB

01/25/2019

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

01/05/2019

RFRR

REFUSAL PROCESSED BY MPU

01/05/2019

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/20/2018

CNRT

NON-FINAL ACTION WRITTEN

12/19/2018

DOCK

ASSIGNED TO EXAMINER

12/18/2018

MAFR

APPLICATION FILING RECEIPT MAILED

12/01/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

11/27/2018

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

11/26/2018

SDRC

SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

11/15/2018

Continuous trademark protection

Get notified about every new filing that threatens DERMOPLASMINE or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.